Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vidaza

Celgene building

Celgene hopes for second time lucky for ozanimod FDA filing

One of six key drugs for BMS-Celgene merger

- PMLiVE

Celgene and Exscientia sign AI drug discovery deal in oncology and autoimmunity

Firm says it cuts discovery timelines by 75%

Bristol Myers Squibb logo

BMS defends Celgene buyout ahead of shareholder vote

BMS battles for hearts and minds before shareholder vote

- PMLiVE

Celgene’s Abraxane fails pancreatic cancer trial

Abraxane failed to show improvement in disease-free survival

Bristol-Myers Squibb (BMS) building

BMS trades blows with investor on Celgene deal merits

Activist investors claim Celgene’s pipeline is “extremely risky”

Bristol-Myers Squibb (BMS) building

Reluctant shareholders threaten $74bn BMS merger with Celgene

Shareholders claim merger undervalues BMS but analysts convinced the deal will close

Celgene building

FDA begins speedy review of Celgene’s Revlimid combo in lymphoma

R2 met its primary endpoint of PFS in trials

Celgene building

BMS and Celgene announce $74bn merger

Huge news for sector, with new fourth-placed company to be created

- PMLiVE

Dragonfly signs Celgene as partner for NK cell platform

Extends presence in haemato-oncology and solid tumours

Celgene building

ASH18: CAR-T and drugs give new options for multiple myeloma

San Diego congress showcasing data in important haematology markets

Celgene building

Celgene to launch five new products through to 2020

Two of which are CAR-T candidates

Celgene building

Celgene’s Revlimid gets a win in late-stage lymphoma

Patients on Revlimid and Roche’s Rituxan saw boosted PFS rates

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links